{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
INN:dazdotuftide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ramorelix is a glycosylated gonadoliberin antagonist patented by Hoechst A.-G. as an anticancer agent. In preclinical studies, a single injection of ramorelix microparticles inhibited tumor progression for only 14 days. This short action is due to a different release profile of the ramorelix microparticles and the different specific activities of peptides incorporated. In the preventive experiments, animals were treated 17 days after DMBA induction before tumor development. Treatment with buserelin implants every 56 days or with buserelin microparticles every 28 days and the treatment with ramorelix microparticles every 7 days prevented the development of tumors. Six weeks after the last injection of ramorelix microparticles a strong tumor progression was seen. There was a clear correlation between peptide release and tumor inhibition. The implants and the microparticles were well tolerated, no tissue reaction or side-effects of ramorelix were seen.
Status:
Investigational
Source:
NCT01987284: Phase 2 Interventional Completed Isolated Systolic Hypertension
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
SER-100 (previously known as ZP120, Ac-RYYRWKKKKKKK-NH2) is a peripherally acting orphanin FQ/nociceptin (ORL-1) receptor agonist that is in development with Serodus Pharmaceuticals for the treatment of Isolated systolic hypertension. SER-100 is a peripherally acting, highly potent and selective NOP receptor partial agonist, which was developed by coupling a chain of six lysine residues to an existing NOP receptor partial agonist hexapeptide, Ac-RYYRWK-NH2 to improve meta-bolic stability. SER-100 has sodium-potassium-sparing aquaretic and anti-natriuretic activity. SER-100 exerts a chronic hypotensive and bradycardic effects in rodents, including models of systemic and pulmonary hypertension. SER-100 produces its cardiovascular effects, at least in part, by inhibition of cardiac and vascular sympathetic activity. In terms of clinical evaluation, SER-100 was originally assessed in a randomized, double-blind, placebo controlled Phase II trial as add-on therapy in patients with sub-acute decompensated chronic heart failure (NCT00283361); how-ever, the clinical development of the peptide for this indication was terminated prematurely due to significant hypotensive activity, primarily on systolic blood pressure (SBP). Nonetheless, as a result of this profound drop in SBP, SER-100 (10 mg, s.c., bid) was investigated in a randomized, placebo-controlled study in patients with treatment-resistant isolated systolic hypertension (NCT01987284) and found to produce a meaningful and long lasting drop in SBP(~7 mmHg) and diastolic (~4 mmHg) blood pressure (DBP),as well as being safe and well-tolerated. FDA has granted an Orphan Drug Designation for SER-100 in pulmonary arterial hypertension (PAH).
Status:
Investigational
Source:
NCT03604757: Phase 2 Interventional Completed Prostate Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
JAN:LATROMOTIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LATROMOTIDE is a synthetic peptide with antineoplastic activity. It consists of 10 amino acid corresponding to amino acid residues 66-75 of human kinesin-like protein KIF20A.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Deltibant is the bradykinin receptor antagonist. It was found to be a potent and selective inhibitor of the depressor response to bradykinin in the anaesthetized rat and rabbit. Deltibant affords significant protection against traumatic shock where bradykinin plays an important role in tissue injury. Such protection may be achieved through inhibition of neutrophil-endothelial interaction and protection of vascular endothelial function. Deltibant may have some effect on survival in patients with systemic inflammatory response syndrome and gram-negative sepsis. Kinin-kallikrein system could be involved in cerebral edema - treatment with deltibant appeared to alter the natural history of traumatic brain contusions by preventing the 2 degrees brain swelling. In addition, deltibant obviated the need for surgery in the majority of treated patients. Deltibant could act on the cerebral vasculature to limit dys-autoregulation and brain swelling or on the blood brain barrier to reduce cerebral edema. Deltibant has been in phase II clinical trials for the treatment of pain, immune-inflammatory diseases and stroke. However, this research has been discontinued.
Status:
Investigational
Source:
NCT00884845: Phase 1 Interventional Completed Advanced Malignant Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Elisidepsin (Irvalec®, PM02734) is a depsipeptide produced by chemical synthesis and chosen for development as an antineoplastic agent based on its in vitro activity against human solid tumor cell lines, in vivo activity in hollow fibers and xenografted human tumors, as well as its acceptable preclinical toxicology profile. Elisidepsin causes a typical necrotic cell death and induces profound alterations in tumor cell morphology. Elisidepsin inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PharmaMar was developing elisidepsin for the treatment of cancer. However, development of the compound has been suspended.
Status:
Investigational
Source:
NCT01578564: Phase 1 Interventional Completed Cancer
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
SOR-C13, is a novel, short, synthetic peptide developed from the C-terminal region of soricidin, a proprietary 54 amino acid peptide, discovered by Soricimed Biopharma found in the saliva of the Northern Short-tailed Shrew. SOR-C13 binds with high affinity and selectivity - and disrupts the function of - TRPV6, a calcium channel over-expressed in solid tumor cancers. TRPV6 plays a central role in a biochemical cascade that results in the upregulation of an array of pro-cancerous genes. TRPV6 is considered to be an important target for novel anticancer therapy. SOR-C13 is the first highly specific TRPV6 inhibitor to be identified and to be taken into clinical development. SOR-C13 was effective in inhibition of tumors in animal xenograft models of human ovarian and breast cancer. The ongoing phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors. The FDA has awarded orphan drug status to SOR-C13 for the treatment of ovarian cancer and for the treatment of pancreatic cancer.
Status:
Investigational
Source:
NCT04231968: Phase 3 Interventional Completed Respiratory Syncytial Virus Infections
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03926182: Phase 1 Interventional Completed Healthy Male Volunteers
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
